These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 23225517)

  • 1. Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective.
    Leleux J; Roy K
    Adv Healthc Mater; 2013 Jan; 2(1):72-94. PubMed ID: 23225517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering vaccines and niches for immune modulation.
    Purwada A; Roy K; Singh A
    Acta Biomater; 2014 Apr; 10(4):1728-40. PubMed ID: 24373907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol.
    Augustin MA; Sanguansri L; Lockett T
    Ann N Y Acad Sci; 2013 Jul; 1290():107-12. PubMed ID: 23855472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting nanoparticles to dendritic cells for immunotherapy.
    Cruz LJ; Tacken PJ; Rueda F; Domingo JC; Albericio F; Figdor CG
    Methods Enzymol; 2012; 509():143-63. PubMed ID: 22568905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward therapeutic delivery with layer-by-layer engineered particles.
    Yan Y; Such GK; Johnston AP; Lomas H; Caruso F
    ACS Nano; 2011 Jun; 5(6):4252-7. PubMed ID: 21612259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems.
    Gupta RK; Chang AC; Siber GR
    Dev Biol Stand; 1998; 92():63-78. PubMed ID: 9554260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunity in response to particulate antigen-delivery systems.
    Storni T; Kündig TM; Senti G; Johansen P
    Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal vaccines--targeting the delivery of antigen.
    Altin JG; Parish CR
    Methods; 2006 Sep; 40(1):39-52. PubMed ID: 16997712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
    Nordly P; Madsen HB; Nielsen HM; Foged C
    Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
    Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
    J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of animal models in the development of human vaccines.
    Gerdts V; Littel-van den Hurk Sv; Griebel PJ; Babiuk LA
    Future Microbiol; 2007 Dec; 2(6):667-75. PubMed ID: 18041907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
    Hamdy S; Haddadi A; Hung RW; Lavasanifar A
    Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
    Klippstein R; Pozo D
    Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high-throughput microparticle microarray platform for dendritic cell-targeting vaccines.
    Acharya AP; Clare-Salzler MJ; Keselowsky BG
    Biomaterials; 2009 Sep; 30(25):4168-77. PubMed ID: 19477505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
    Speiser DE; Romero P
    Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting dendritic cells with biomaterials: developing the next generation of vaccines.
    Reddy ST; Swartz MA; Hubbell JA
    Trends Immunol; 2006 Dec; 27(12):573-9. PubMed ID: 17049307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Particle-based vaccines for transcutaneous vaccination.
    Combadière B; Mahé B
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):293-315. PubMed ID: 17915323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.